Biologics Met Primary End Points for Sjögren Disease
New treatments from Novartis and Amgen have reached clinical milestones, offering hope for Sjögren disease patients.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you trust that new targeted therapies will lower the financial burden for patients with chronic diseases?
Clinical trials for the biologics ianalumab and dazodalibep have met their primary end points in the treatment of Sjögren disease. These results offer a potential breakthrough for patients, as no FDA-approved disease-modifying treatments currently exist for the condition.
Why it matters
Patients living with Sjögren disease face significantly higher healthcare burdens and lost productivity compared to those without the condition. Developing effective therapies remains a high priority because the current standard of care lacks options that target the disease's root causes.
Novartis' ianalumab works by binding to BAFF-R to deplete B cells, while Amgen's dazodalibep disrupts the interaction between T cells and B cells. Trials for ianalumab and the OASIZ 301 study for dazodalibep have confirmed these targeted biological mechanisms.
The players
Novartis
This multinational pharmaceutical corporation is the developer of ianalumab, an investigational therapy targeting B cells.
Amgen
This biotechnology company is the developer of dazodalibep, which is currently being tested in phase 3 clinical trials.
China National Medical Products Administration
This is the primary regulatory agency responsible for overseeing and approving medical products and drugs within China.
The details
Ianalumab and dazodalibep represent significant developments in immunotherapy for an condition that currently lacks a disease-modifying, FDA-approved treatment. With 621 adults enrolled in the OASIZ 301 trial alone, the scale of current testing underscores the urgency to address the 66 hours of average short-term disability incurred by patients.
Timeline
January 16, 2026: FDA granted ianalumab breakthrough therapy designation.
June 8, 2026: China approved telitacicept for Sjögren disease treatment.
September 22, 2026: Amgen reported positive phase 3 results for dazodalibep.
Q4 2026: Expected completion date for the OASIZ 303 trial.
The Tech Race
The clinical success of these biologics reflects a broader industry shift toward targeted immunotherapies that address the underlying mechanisms of autoimmune disorders. This move away from legacy symptom management mirrors the development of advanced monoclonal antibodies that have already redefined treatment paradigms in oncology and rheumatology.
For patients, these developments signal the potential for future access to disease-modifying treatments that could reduce the need for emergency care and improve daily functional capacity. These therapies aim to alleviate the significant financial and personal strain caused by high healthcare costs and productivity loss.
The takeaway
These clinical breakthroughs offer hope for a shift in standard care for chronic autoimmune patients. Future market availability depends on upcoming trial completions and successful navigation of global regulatory hurdles.
What happens next
The OASIZ 303 trial is scheduled to be completed in the fourth quarter of 2026, which will provide additional efficacy data for dazodalibep.
Further reading
For more information on the evolving landscape of immunological therapies, visit the Biotech section.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that new targeted therapies will lower the financial burden for patients with chronic diseases?
